US Dermatologists Report a Sizeable Portion of Their Atopic Dermatitis Patients Currently Treated with Sanofi/Regeneron's Dupixent Would be Switched to Another Targeted Therapy if Available
Advertisement
According to a recent study conducted by Spherix Global Insights, Dupixent continues to be well-received amongst US dermatologists, though overall use will likely take a hit once new advance systemic treatments become available.
